s / Drug and Alcohol Dependence 146 (2015) e202–e284 e221 activities in each category focusing on the first three and will describe an app developed for professionals. Conclusions: Informed planning of dissemination activities by a trusted source such as a professional association that attends to members’ concerns may increase acceptance of evidence-based practices. Some barriers, however, remain difficult to overcome. Financial support: AHRQ provides partial support. http://dx.doi.org/10.1016/j.drugalcdep.2014.09.067 Dose and other factors associated with decreased pain intensity among patients initiating buprenorphine/naloxone William Becker1,2, Dara Ganoczy3, David Fiellin2, Amy S. Bohnert3 1 VA Connecticut, West Haven, CT, United States 2 Yale University, New Haven, CT, United States 3 Ann Arbor VA, Ann Arbor, MI, United States Aims: Opioid use disorder (OUD) and pain often co-occur, complicating the treatment of each condition. Owing to its partial agonist properties, buprenorphine/naloxone (BUP/NX) may confer advantages over full agonist opioids for treatment of both conditions. The optimal dose of BUP/NX for comorbid pain is not known. We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. Methods: We studied 1171 patients initiating BUP/NX treatment for OUD from 2004 to 2010. Eligible patients had >1 pain intensity numerical rating score (NRS) within 30 days before BUP/NX initiation (baseline) and >1 NRS between 15 and 90 days after BUP/NX initiation (within treatment). The primary outcome wasa clinically significantNRSdecrease (2or greater) frombaseline to within treatment. We used descriptive statistics to summarize baseline characteristics and BUP/NX doses and bivariate measures to assess the relationship between independent variables and change inpain intensity.Weusedgeneralized estimating equations to model odds of ≥2 NRS decrease, with BUP/NX dose as the independent variable of interest in the subset of patientswith a baseline NRS>2. Results: The samplewas94%male and73%white.Meanagewas 50. 30% of the sample had PTSD, 63% had major depression, while 44%hadalcohol usedisorder and75%hadnon-opioid substanceuse disorders. In bivariate analysis, patients without major depression and patients with cancer were more likely to have improved pain intensity with initiation of BUP/NX. In the subset analysis, the following demographic and clinical correlates were associated with a clinically significant decrease in pain intensity: age 18–29 (compared to 30–39 and40–49); absence of PTSDand absence of chronic pain. BUP/NXdosewasnotassociatedwithdecreasedpain intensity in bivariate or multivariable analysis. Conclusions: These findings suggest that factors other than BUP/NX dose contribute to improved pain intensity among those initiating it. Financial support: VA HSRD SUD QUERI (SUDQ-LIP1302). http://dx.doi.org/10.1016/j.drugalcdep.2014.09.068 The effect of marijuana commercialization on adolescent polysubstance use and treatment Katherine Belendiuk1, Taylor Black1, Christian Thurstone1,2 1 Department of Psychiatry, University of Colorado, Aurora, CO, United States 2 Denver Health and Hospital Authority, Denver, CO,